David Cory

Chief Executive Officer

David Cory is an industry veteran with more than 30 years of operational experience in private and public, emerging-stage biotech and large pharmaceutical companies with an established track record of building and leading high performing clinical and regulatory development teams, overseeing commercial launch of 20 approved pharmaceutical brands across therapeutic indications and raising over $1B+ in the capital markets with multiple company exits by acquisition.

Most recently, Mr. Cory was CEO and Director of LIB Therapeutics which completed Phase 3 global registration-enabling trials for its lead cardiovascular disease program and filed for regulatory approval. Previously, Mr. Cory was CEO and Director of Eiger BioPharmaceuticals which obtained FDA and EMA approval and launched the first therapy to extend survival in Hutchinson-Gilford progeria syndrome, an ultra-rare and fatal pediatric disease. Mr. Cory began his emerging-stage biotech career as a founding member and/or executive in multiple start-up companies including InterMune, CoTherix, and Prestwick Pharmaceuticals which resulted in exits by acquisition of approximately $9 billion collectively. Mr. Cory began his industry career spending over a decade in large global pharma holding positions of increasing operational responsibility at The Upjohn Company and Glaxo-Smith Kline. Mr. Cory earned a BS in Pharmacy from the University of Cincinnati, College of Pharmacy, was board certified in Pharmacy and holds an MBA from the University of Maryland.